Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2011

01-12-2011 | Research Article

High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy

Authors: Hongxia Zhu, Qifeng Wang, Chenfei Hu, Wencheng Zhang, Lanping Quan, Mei Liu, Ningzhi Xu, Zefen Xiao

Published in: Tumor Biology | Issue 6/2011

Login to get access

Abstract

Radiotherapy is one of the main treatments for esophageal squamous cell carcinoma, but there are still no biomarkers to differentiate patients who will benefit from radiation. Although treatment with a combination of radiotherapy with chemotherapy, and/or surgery improves the prognosis of patients, no biomarkers can distinguish between the responses obtained with the combined therapies. Therefore, in this study, we selected patients treated with radiotherapy alone to evaluate survivin as a predictor for radiotherapy. One hundred two biopsy samples collected by endoscopy were immunostained by survivin antibody. Positive staining for survivin was obtained in 60.8% tumor samples. Survivin expression, metastasis, and clinical stage correlated significantly with overall survival. In multivariate analysis, survivin was an independent prognostic factor for predicting overall survival of patients with esophageal cancer. Moreover, in esophageal cancer cell lines, overexpression of survivin reduced the percentage of cell death induced by radiation. Our data indicate that survivin could be a potential predictor to define those patients with esophageal squamous carcinoma who would benefit from radiotherapy.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zhang S, Lei Z, Li G, Zou X, Zhao P, Chen W. A report of cancer incidence and mortality from 34 cancer registries in China, 2006. China Cancer. 2010;19:356–65. in Chinese.
3.
Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, et al. Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer. 2004;91:1543–50.PubMedCrossRef
4.
Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y, et al. Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis. Dis Esophagus. 2008;21:288–97.PubMedCrossRef
5.
Chen MF, Fang FM, Lu CH, Lu MS, Chen WC, Lee KD, et al. Significance of nuclear accumulation of Foxo3a in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2008;71:1220–9.PubMedCrossRef
6.
Metzger R, Heukamp L, Drebber U, Bollschweiler E, Zander T, Hoelscher AH, et al. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics. 2010;11:1105–13.PubMedCrossRef
7.
Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H, et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther. 2004;11:1215–23.PubMedCrossRef
8.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.PubMedCrossRef
9.
Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9.PubMedCrossRef
10.
Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, et al. Survivin and escaping in therapy-induced cellular senescence. Int J Cancer. 2011;128:1546–58.PubMedCrossRef
11.
Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999–6002.PubMedCrossRef
12.
13.
Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, et al. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 2006;119:1717–22.PubMedCrossRef
14.
Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15:7012–9.PubMedCrossRef
15.
Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61–70.PubMedCrossRef
16.
Lei Y, Geng Z, Guo-Jun W, He W, Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem. 2010;344:23–31.PubMedCrossRef
17.
Freier K, Pungs S, Sticht C, Flechtenmacher C, Lichter P, Joos S, et al. High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer. 2007;120:942–6.PubMedCrossRef
18.
Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Suzuki Y, et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol. 2009;91:353–8.PubMedCrossRef
19.
Zhu HX, Wang YH, Zhou CQ, Zhang G, Bai JF, Quan LP, et al. Expression of survivin and its significance in esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2005;27:22–4. In Chinese.PubMed
20.
Zhu HX, Liu S, Zhou CQ, Zhou XB, Zhang F, Quan LP, et al. Anti-apoptosis gene survivin promotes cell growth and transformation. Zhonghua Yi Xue Za Zhi. 2002;82:338–40. in Chinese.PubMed
21.
Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011;29:161–6.PubMedCrossRef
22.
Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27:4481–6.PubMedCrossRef
23.
Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68:505–11.PubMedCrossRef
24.
Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer. 2002;87:883–7.PubMedCrossRef
25.
Takeno S, Yamashita S, Takahashi Y, Ono K, Kamei M, Moroga T, et al. Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression. Eur J Cardiothorac Surg. 2010;37:440–5.PubMed
26.
Grabowski P, Kühnel T, Mühr-Wilkenshoff F, Heine B, Stein H, Höpfner M, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003;88:115–9.PubMedCrossRef
27.
Vallböhmer D, Kuhn E, Warnecke-Eberz U, Brabender J, Hoffmann AC, Metzger R, et al. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2008;9:681–90.PubMedCrossRef
28.
Warnecke-Eberz U, Hokita S, Xi H, Higashi H, Baldus SE, Metzger R, et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep. 2005;13:1241–6.PubMed
29.
Capalbo G, Dittmann K, Weiss C, Reichert S, Hausmann E, Rödel C, et al. Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys. 2010;77:226–34.PubMedCrossRef
Metadata
Title
High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy
Authors
Hongxia Zhu
Qifeng Wang
Chenfei Hu
Wencheng Zhang
Lanping Quan
Mei Liu
Ningzhi Xu
Zefen Xiao
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0217-y

Other articles of this Issue 6/2011

Tumor Biology 6/2011 Go to the issue

Review

PDGF: the nuts and bolts of signalling toolbox

Research Article

Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients

Research Article

Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifying biomarkers of laryngeal carcinoma

Research Article

The expression of p33ING1, p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer

Research Article

Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis

Research Article

Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits